Table 4.
Univariate and multivariate analyses of risk factors for progression-free survival
| Factors |
Univariate analysis
|
Multivariate analysis
|
||||
|
HR
|
95%CI
|
P value
|
HR
|
95%CI
|
P value
|
|
| Sex | ||||||
| Male/female | 1.145 | 0.692-49 | 0.599 | |||
| Age (years) | 1.007 | 0.987-1.027 | 0.495 | |||
| ECOG PS | ||||||
| 0/1 | 1.246 | 0.781-1.988 | 0.357 | |||
| Child-Pugh class | ||||||
| A/B | 1.301 | 0.881-1.921 | 0.185 | |||
| AFP (ng/mL) | ||||||
| ≤ 400/> 400 | 1.215 | 0.821-1.798 | 0.329 | |||
| Number of tumors | ||||||
| ≤ 3/> 3 | 1.276 | 0.857-1.900 | 0.229 | |||
| Largest tumor size (mm) | 1.006 | 0.998-1.013 | 0.139 | |||
| PVTT | ||||||
| No/yes | 1.590 | 1.073-2.358 | 0.021 | 1.670 | 1.120-2.491 | 0.012 |
| Hepatic vein invasion | ||||||
| No/yes | 1.621 | 1.012-2.596 | 0.044 | 1.807 | 1.105-2.956 | 0.018 |
| Extrahepatic metastasis | ||||||
| No/yes | 1.778 | 1.038-3.044 | 0.036 | 1.554 | 0.900-2.686 | 0.114 |
| Treatment option | ||||||
| D-TACE-P-L/C-TACE-P-L | 1.422 | 0.961-2.104 | 0.078 | 1.536 | 1.028-2.293 | 0.036 |
C-TACE-P-L: Conventional transarterial chemoembolization combined with lenvatinib plus programmed cell death 1 inhibitor; D-TACE-P-L: Drug-eluting beads transarterial chemoembolization combined with lenvatinib plus programmed cell death 1 inhibitor; ECOG PS: Eastern Cooperative Oncology Group Performance Status; AFP: Alpha-fetoprotein; PVTT: Portal vein tumor thrombus; HR: Hazard ratio; CI: Confidence interval.